Perrigo Takes Another Step On Planned Generic Exit
Divestiture Takes It Closer To Being A Consumer-Focused Self-Care Firm
Perrigo’s ambitions to become a consumer-focused company are a step closer after the firm announced an immediate sale of a ‘non-core’ asset.
You may also be interested in...
Juno Pharmaceuticals has struck a deal that will see it act as the exclusive distributor for UK-based Rosemont’s oral liquid medicines in Canada.
Perrigo has completed the divestment of its Rx prescription generics business to Altaris Capital Partners for $1.55bn, completing its transition to become a self-care consumer healthcare-focused company. Altaris has rebranded the unit as Padagis.
A year on from being spun-out of Perrigo and acquired by private equity, liquid generics specialist Rosemont Pharmaceuticals has revealed new details of the UK-based firm’s operations.